{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-25-000069","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.223491+00:00","generated_at":"2026-05-23T05:02:02.078869+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arvinas reports preclinical combo data for PROTAC BCL6 degrader ARV-393 with complete regressions in lymphoma","bullets":["ARV-393 plus R-CHOP induced complete tumor regressions in all mice, outperforming single agents alone.","Combination with SOC biologics (rituximab, tafasitamab, polatuzumab vedotin) resulted in tumor regressions in DLBCL models.","ARV-393 increased CD20 expression in preclinical models, supporting combinations with CD20-targeted agents.","Combination with investigational SMIs (acalabrutinib, venetoclax, tazemetostat) showed superior growth inhibition with regressions.","Phase 1 study for ARV-393 (NCT06393738) enrolling patients with relapsed/refractory non-Hodgkin lymphoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-25-000069","json":"https://secwatch.observer/filing/0001655759-25-000069.json","markdown":"https://secwatch.observer/filing/0001655759-25-000069.md","text":"https://secwatch.observer/filing/0001655759-25-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000069/0001655759-25-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000069/arvn-20250428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:02:02.078869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}